Trials / Completed

CompletedNCT00498654

Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of a Single Oral Dose Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 180 (estimated)

Sponsor: Avant Immunotherapeutics · Industry
Sex: All
Age: 18 Years – 55 Years
Healthy volunteers: Accepted

Summary

The purpose of this trial is to examine the safety and immunogenicity of Ty800 oral vaccine in healthy adult subjects.

Conditions

Typhoid Fever

Interventions

Type	Name	Description
BIOLOGICAL	Ty800 (Salmonella typhi) Oral Vaccine

Timeline

Start date: 2007-07-01
Primary completion: 2007-10-01
Completion: 2008-06-01
First posted: 2007-07-10
Last updated: 2008-07-02

Locations

5 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00498654. Inclusion in this directory is not an endorsement.